keyword
MENU ▼
Read by QxMD icon Read
search

Myeloid neoplasm

keyword
https://www.readbyqxmd.com/read/29907599/aggressive-b-cell-lymphomas-in-patients-with-myelofibrosis-receiving-jak1-2-inhibitor-therapy
#1
Edit Porpaczy, Sabrina Tripolt, Andrea Hoelbl-Kovacic, Bettina Gisslinger, Zsuzsanna Bago-Horvath, Emilio Casanova-Hevia, Emmanuelle Clappier, Thomas Decker, Sabine Fajmann, Daniela A Fux, Georg Greiner, Sinan Gueltekin, Gerwin Heller, Harald Herkner, Gregor Hoermann, Jean-Jacques Kiladjian, Thomas Kolbe, Christoph Kornauth, Maria-Theresa Krauth, Robert Kralovics, Leonhard Muellauer, Mathias Mueller, Michaela Prchal-Murphy, Eva Maria Putz, Emmanuel Raffoux, Ana-Iris Schiefer, Klaus Schmetterer, Christine Schneckenleithner, Ingrid Simonitsch-Klupp, Cathrin Skrabs, Wolfgang R Sperr, Philipp Bernhard Staber, Birgit Strobl, Peter Valent, Ulrich Jaeger, Heinz Gisslinger, Veronika Sexl
Inhibition of Janus-kinase 1/2 (JAK1/2) is a mainstay to treat myeloproliferative neoplasms (MPN). Sporadic observations reported the co-incidence of B-cell non-Hodgkin lymphomas during treatment of MPN with JAK1/2 inhibitors. We assessed 626 MPN patients including 69 with myelofibrosis receiving JAK1/2 inhibitors for lymphoma development. B-cell lymphomas evolved in 4/69 patients (5.8%) upon JAK1/2 inhibition compared to 2/557 (0.36%) with conventional treatment (16-fold increased risk). A similar 15-fold increase was observed in an independent cohort of 929 MPN patients...
June 14, 2018: Blood
https://www.readbyqxmd.com/read/29903756/therapy-related-acute-lymphoblastic-leukemia-has-distinct-clinical-and-cytogenetic-features-compared-to-de-novo-acute-lymphoblastic-leukemia-but-outcomes-are-comparable-in-transplanted-patients
#2
Ibrahim Aldoss, Tracey Stiller, Ni-Chun Tsai, Joo Y Song, Thai Cao, N Achini Bandara, Amadeep Salhotra, Samer Khaled, Ahmed Aribi, Monzr M Al Malki, Matthew Mei, Haris Ali, Ricardo Spielberger, Margaret O'Donnell, David Snyder, Thomas Slavin, Ryotaro Nakamura, Anthony S Stein, Stephen J Forman, Guido Marcucci, Vinod Pullarkat
Therapy-related acute lymphoblastic leukemia remains poorly defined due to a lack of large data sets recognizing the defining characteristics of this entity. We reviewed all consecutive cases of adult acute lymphoblastic leukemia treated at our institution between 2000 and 2017 and identified therapy-related cases-defined as acute lymphoblastic leukemia preceded by prior exposure to cytotoxic chemotherapy and/or radiation. Of 1022 patients with acute lymphoblastic leukemia, 93 (9.1%) were classified as therapy-related...
June 14, 2018: Haematologica
https://www.readbyqxmd.com/read/29892548/anti-cd19-chimeric-antigen-receptor-targeting-of-cd19-acute-myeloid-leukemia
#3
Gina Ma, Yi Wang, Tahmeena Ahmed, Ann-Leslie Zaslav, Laura Hogan, Cecilia Avila, Masayuki Wada, Huda Salman
Aberrant expression of CD19 in acute myeloid leukemia (AML) is commonly associated with t(8;21)(q22;q22), although AML cases lacking this translocation occasionally express CD19. Mixed-phenotype acute leukemia also frequently expresses CD19. Chimeric antigen receptor (CAR) technology is a major breakthrough for cancer treatment, with the recent approval of CD19-directed CAR (CD19CAR) for treating B-cell malignancies. However, little information exists on using CD19CAR for other CD19 positive neoplasms such as AML...
2018: Leukemia Research Reports
https://www.readbyqxmd.com/read/29884903/mutation-specific-signaling-profiles-and-kinase-inhibitor-sensitivities-of-juvenile-myelomonocytic-leukemia-revealed-by-induced-pluripotent-stem-cells
#4
Sarah K Tasian, Jessica A Casas, David Posocco, Shilpa Gandre-Babbe, Alyssa L Gagne, Ge Liang, Mignon L Loh, Mitchell J Weiss, Deborah L French, Stella T Chou
Juvenile myelomonocytic leukemia (JMML) is an uncommon myeloproliferative neoplasm driven by Ras pathway mutations and hyperactive Ras/MAPK signaling. Outcomes for many children with JMML remain dismal with current standard-of-care cytoreductive chemotherapy and hematopoietic stem cell transplantation. We used patient-derived induced pluripotent stem cells (iPSCs) to characterize the signaling profiles and potential therapeutic vulnerabilities of PTPN11-mutant and CBL-mutant JMML. We assessed whether MEK, JAK, and PI3K/mTOR kinase inhibitors (i) could inhibit myeloproliferation and aberrant signaling in iPSC-derived hematopoietic progenitors with PTPN11 E76K or CBL Y371H mutations...
June 8, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/29884520/atypical-presentation-of-blastic-plasmacytoid-dendritic-cell-neoplasm-a-potential-diagnostic-pitfall-in-nasal-cavity
#5
Fang Yu, Ke Sun, Zhaoming Wang
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare disease with an aggressive clinical course resulting in median survival times of 12 to 14 months.1 It represents approximately 0.8% of primary cutaneous lymphomas.2 According to the World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissue, published in 2008, BPDCN is defined as an acute myeloid leukemia related precursor neoplasm, derived from precursors of the plasmacytoid dendritic cell. It is characterized microscopically by its dense monomorphous infiltrates of medium-sized blastoid morphology and expression of CD4 and CD56, as well as the absence of any common myeloid, T-lymphoid, B-lymphoid, and natural killer-lymphoid lineage markers...
May 3, 2018: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
https://www.readbyqxmd.com/read/29878489/chronic-myelomonocytic-leukemia-2018-update-on-diagnosis-risk-stratification-and-management
#6
Mrinal M Patnaik, Ayalew Tefferi
DISEASE OVERVIEW: Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder with overlapping features of myelodysplastic syndromes and myeloproliferative neoplasms, with an inherent risk for leukemic transformation (∼15%-20% over 3-5 years). DIAGNOSIS: Diagnosis is based on the presence of sustained (>3 months) peripheral blood monocytosis (≥1 × 109 /L; monocytes ≥10%), along with bone marrow dysplasia. Clonal cytogenetic abnormalities occur in ∼ 30% of patients, while >90% have gene mutations...
June 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29876349/detection-of-central-nervous-system-infiltration-by-myeloid-and-lymphoid-hematologic-neoplasms-using-flow-cytometry-analysis-diagnostic-accuracy-study
#7
Laiz Cameirão Bento, Rodolfo Patussi Correia, Anderson Marega Alexandre, Sonia Tsukasa Nosawa, Eduardo de Carvalho Pedro, Andressa da Costa Vaz, Daniela Schimidell, Gustavo Bruniera Peres Fernandes, Carlos Augusto Senne Duarte, Rodrigo de Souza Barroso, Nydia Strachman Bacal
Introduction: Infiltration of the central nervous system (CNS) by hematologic or lymphoid malignant cells can cause extensive neurological damage, be progressive and fatal. However, usually, the cerebrospinal fluid (CSF) has low cellularity and rapid cell degeneration, which can impair cytometry analysis. Storage and transport measures, sample preparation, and staining protocols can interfere with diagnostic accuracy. Objective: To calculate the diagnostic performance of flow cytometry (FC) using a cell stabilizer for sample preservation compared to cytomorphology in the detection of CNS infiltration by lymphoid and hematologic neoplasms...
2018: Frontiers in Medicine
https://www.readbyqxmd.com/read/29872884/myeloid-neoplasms-with-t-16-21-q24-q22-runx1-runx1t3-mimics-acute-myeloid-leukemia-with-runx1-runx1t1
#8
Huifei Liu, Sa A Wang, Ellen J Schlette, Jie Xu, Jeffrey L Jorgensen, C Cameron Yin, Shaoying Li, L Jeffrey Medeiros, Guilin Tang
Chromosome translocation t(16;21)(q24;q22)/RUNX1-RUNX1T3 is an infrequent but recurrent chromosomal abnormality identified in myeloid neoplasms, with only 25 cases have been reported to date. Here, we report eight cases (six women and two men) of myeloid neoplasms associated with t(16;21)(q24;q22): five with therapy-related myeloid neoplasms, two with relapsed acute myeloid leukemia (AML), and one with blast phase of chronic myeloid leukemia. Morphologic and immunophenotypic features include granulocytic dysplasia, blasts with prominent perinuclear hof, large orange-pink granules, long and slim Auer rods, and aberrant expression of CD19...
June 5, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29868474/therapeutic-antibodies-for-myeloid-neoplasms-current-developments-and-future-directions
#9
REVIEW
Christian M Schürch
Therapeutic monoclonal antibodies (mAbs) such as antibody-drug conjugates, ligand-receptor antagonists, immune checkpoint inhibitors and bispecific T cell engagers have shown impressive efficacy in the treatment of multiple human cancers. Numerous therapeutic mAbs that have been developed for myeloid neoplasms, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), are currently investigated in clinical trials. Because AML and MDS originate from malignantly transformed hematopoietic stem/progenitor cells-the so-called leukemic stem cells (LSCs) that are highly resistant to most standard drugs-these malignancies frequently relapse and have a high disease-specific mortality...
2018: Frontiers in Oncology
https://www.readbyqxmd.com/read/29868471/the-role-of-macrophage-b-cell-interactions-in-the-pathophysiology-of-b-cell-lymphomas
#10
REVIEW
Lan V Pham, Elizabeth Pogue, Richard J Ford
Macrophages (MPs) are heterogeneous, multifunctional, myeloid-derived leukocytes that are part of the innate immune system, playing wide-ranging critical roles in basic biological activities, including maintenance of tissue homeostasis involving clearance of microbial pathogens. Tumor-associated MPs (TAMs) are MPs with defined specific M2 phenotypes now known to play central roles in the pathophysiology of a wide spectrum of malignant neoplasms. Also, TAMs are often intrinsic cellular components of the essential tumor microenvironment (TME)...
2018: Frontiers in Oncology
https://www.readbyqxmd.com/read/29864110/hematologic-malignancies-associated-with-mediastinal-germ-cell-tumors-10-years-experience-at-thailand-s-national-pediatric-tertiary-referral-center
#11
Panjarat Sowithayasakul, Phakatip Sinlapamongkolkul, Jitsupa Treetipsatit, Nassawee Vathana, Nattee Narkbunnam, Kleebsabai Sanpakit, Jassada Buaboonnam
Mediastinal germ cell tumor (MGCT), which accounts for 1% to 3% of extragonadal germ cell tumors, has unique manifestations; it is associated with several types of hematologic malignancy, particularly myeloid neoplasm. The aim of this study was to report the 10-year incidence, clinical characteristics, and outcomes of MGCT at Thailand's national pediatric tertiary referral center. This retrospective study included patients diagnosed with MGCT at the Department of Pediatrics, Siriraj Hospital during 2005 to 2014...
June 1, 2018: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/29862538/improved-long-term-survival-in-all-sanz-risk-patients-of-newly-diagnosed-acute-promyelocytic-leukemia-treated-with-a-combination-of-retinoic-acid-and-arsenic-trioxide-based-front-line-therapy
#12
Yinjun Lou, Ying Lu, Zhijuan Zhu, Yafang Ma, Shanshan Suo, Yungui Wang, Dong Chen, Hongyan Tong, Wenbin Qian, Haitao Meng, Wenyuan Mai, Wenjun Yu, Weilai Xu, Lei Wang, Liping Mao, Renzhi Pei, Jie Jin
Limited data was available for long-term follow-up in newly diagnosed acute promyelocytic leukemia (APL) patients treated with all-trans-retinoic acid (ATRA) plus intravenously arsenic trioxide (ATO)-based front-line therapy. The aim of this work was to retrospectively analyze the long-term survival rate and frequency of therapy-related myeloid neoplasia (t-MN) occurring in a large cohort of APL patients. A total of 760 newly diagnosed patients with APL between January 1999 and May 2016 were evaluated. The early death rate was 9...
June 3, 2018: Hematological Oncology
https://www.readbyqxmd.com/read/29860246/idiopathic-cytopenia-of-uncertain-significance-idiopathic-dysplasia-of-unknown-significance-clonal-hematopoiesis-with-indeterminate-potential-and-clonal-cytopenia-of-unknown-significance-diagnostic-criteria-separation-from-myelodysplastic-syndromes-and-clinical
#13
Peter Valent
Various myeloid neoplasms, including the myelodysplastic syndromes (MDS), bear a certain risk of progression to secondary acute myeloid leukemia (sAML). The evolution from low-risk to high-risk MDS and finally to sAML suggests that leukemogenesis is a multistep process. However, even before an overt neoplasm, such as an MDS, develops, "prediagnostic" clonal conditions may be identified. With the advent of large-scale genomic screens, such conditions may be detected quite frequently and early in apparently healthy individuals...
June 1, 2018: Pathobiology: Journal of Immunopathology, Molecular and Cellular Biology
https://www.readbyqxmd.com/read/29847855/implications-of-mutation-profiling-in-myeloid-malignancies-part-2-myeloproliferative-neoplasms-and-other-myeloid-malignancies
#14
REVIEW
Kelsey Sokol, Douglas Tremblay, Sheena Bhalla, Raajit Rampal, John O Mascarenhas
Myeloid malignancies arise from the acquisition of somatic mutations among various genes implicated in essential functioning of hematopoietic stem cells and progenitor cells. In this second part of our two-part review, we discuss the use of mutation profiling in the diagnosis, prognosis, and treatment of patients with myeloproliferative neoplasms and other myeloid diseases. We also discuss the entity known as clonal hematopoiesis of indeterminate potential, awareness of which is a result of the increasing availability and improved quality of mutation profiling...
May 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29845291/concomitant-presence-of-jak2v617f-mutation-and-bcr%C3%A2-abl-translocation-in-two-patients-a-new-entity-or-a-variant-of-myeloproliferative-neoplasms-case-report
#15
Filipa Mousinho, Ana P Azevedo, Tatiana Mendes, Paula Sousa E Santos, Rita Cerqueira, Sónia Matos, Sónia Santos, Sância Ramos, João Faro Viana, Fernando Lima
Myeloproliferative neoplasms (MPNs) are classically divided into BCR RhoGEF and GTPase activating protein (BCR)-ABL proto‑oncogene 1 non‑receptor tyrosine kinase (ABL) positive chronic myeloid leukemia (CML) and BCR‑ABL negative MPNs, including essential thrombocythemia (ET). One of the major diagnostic criteria for ET is the absence of the philadelphia chromosome, thus when present it is almost indicative of CML. ET and CML are considered to be mutually exclusive; however, there are rare situations in which patients with ET present positive BCR‑ABL without the features of CML...
May 17, 2018: Molecular Medicine Reports
https://www.readbyqxmd.com/read/29843123/the-critical-role-of-pten-pi3k-akt-signaling-pathway-in-shikonin-induced-apoptosis-and-proliferation-inhibition-of-chronic-myeloid-leukemia
#16
Yu Chen, Tongtong Wang, Jing Du, Yanchun Li, Xin Wang, Yi Zhou, XingXing Yu, Weimin Fan, Qiaojuan Zhu, Xiangmin Tong, Ying Wang
BACKGROUND/AIMS: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm. Tyrosine kinase inhibitors (TKIs) are commonly used to treat CML; however, drug resistance of CML cells to TKIs has limited their clinical application. Shikonin, a traditional Chinese herb, has long been used to treat leukemia in China, but the roles and related molecular mechanisms of shikonin treatment in CML remain unclear. Here, we aimed to evaluate the effects of shikonin on the proliferation, apoptosis, and migration of K562 cells, a CML cell line...
May 24, 2018: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/29806701/neonatal-leukaemia
#17
REVIEW
Irene Roberts, Nicholas J Fordham, Anupama Rao, Barbara J Bain
Neonatal leukaemia is defined as occurring within the first 28 days of life and most, if not all, cases are congenital. With the exception of Down syndrome-associated transient abnormal myelopoiesis, which is not considered here, neonatal leukaemias are rare. In two-thirds of patients the disease manifests as an acute myeloid leukaemia, frequently with monocytic/monoblastic characteristics. Most other cases are acute lymphoblastic leukaemia, particularly B lineage, but some are mixed phenotype or blastic plasmacytoid dendritic cell neoplasms...
May 28, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29805603/acute-lymphoblastic-leukemia-following-temozolomide-treatment-in-a-patient-with-glioblastoma-a-case-report-and-review-of-the-literature
#18
Pengfei Liu, Peiwen Li, Ting Lei, Limei Qu, Haiyan Huang, Qingchun Mu
Temozolomide (TMZ) is a second-generation oral alkylating agent that functions against a number of central nervous system neoplasms, and is generally used to treat high-grade gliomas, including anaplastic astrocytoma and glioblastoma multiforme. Therapy-related secondary myelodysplastic syndrome and acute myeloid leukemia have been reported in patients following prolonged exposure to TMZ. However, TMZ-related acute lymphoblastic leukemia (ALL) is extremely rare. The present study describes the case of an 11-year-old boy with a 3-day history of generalized tonic-clonic seizures and a contrast-enhanced lesion in the left temporooccipital region with focal cystic degeneration, as detected by magnetic resonance imaging...
June 2018: Oncology Letters
https://www.readbyqxmd.com/read/29797808/rejuvenating-aged-hematopoietic-stem-cells-through-improvement-of-mitochondrial-function
#19
REVIEW
James Moon, Hye Ran Kim, Myung Geun Shin
Mitochondria are the powerhouses of the cell as well as the primary site of hematopoiesis, which also occurs in the cytoplasm. Hematopoietic stem cells (HSCs) are characterized by a very high turnover rate, and are thus considered to be relatively free from the age-related insults generated by mitochondria. However, HSCs are also subject to these age-related insults, including the incidence of myeloid proliferative diseases, marrow failure, hematopoietic neoplasms, and deterioration of the adaptive human immune system...
September 2018: Annals of Laboratory Medicine
https://www.readbyqxmd.com/read/29797671/cd7-is-expressed-on-a-subset-of-normal-cd34-positive-myeloid-precursors
#20
Katharina Kriegsmann, Harald Löffler, Volker Eckstein, Renate Schulz, Sandra Kräker, Ute Braun, Thomas Luft, Ute Hegenbart, Stefan Schönland, Peter Dreger, Alwin Krämer, Anthony D Ho, Carsten Müller-Tidow, Michael Hundemer
OBJECTIVE: To improve monitoring of myeloid neoplasms by flow cytometry-based minimal residual disease (MRD) analysis, we analyzed the significance of leukemia-associated immunophenotype (LAIP) markers in 44 patients. METHODS: In a pilot study cohort, peripheral blood or bone marrow samples from 13 patients with myeloid neoplasms and one case of B lymphoblastic leukemia in complete hematologic remission after allogeneic bone marrow or stem cell transplantation were subjected to selection for leukemia-specific phenotypes by fluorescence-activated cell sorting using individual marker combinations, followed by PCR-based chimerism analysis...
May 24, 2018: European Journal of Haematology
keyword
keyword
70874
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"